Case report: rapid and complete control of idiopathic hypereosinophilia with imatinib mesylate - PubMed

Affiliations

• PMID: 11698916

Case Reports

Case report: rapid and complete control of idiopathic hypereosinophilia with imatinib mesylate

J L Schaller et al. MedGenMed. 2001.

Abstract

In this case report, we report what we believe to be the first case of imatinib mesylate or STI-571 (Novartis) use for treatment of idiopathic hypereosinophilia syndrome (HES). HES is often a fatal illness, damaging the heart, nervous system, lungs, liver, and kidneys. It is often treated with interferon-alpha. In this patient, it was combined with hydroxyurea, and we believe it saved his life. However, he experienced many common side effects, such as a profound intractable headache, severe fatigue, and concentration difficulties. After years on hydroxyurea and interferon-alpha, the severity of these side effects motivated us to try a trial of imatinib mesylate. Its use was followed by an abrupt remission of HES in a few weeks, with no significant side effects.

Comment in

• Reader's response to "Rapid and complete control of idiopathic hypereosinophilia with imatinib mesylate".

  Shinkarow JW. Shinkarow JW. MedGenMed. 2007;9(1):39. MedGenMed. 2007. PMID: 17441290 Free PMC article. No abstract available.

Similar articles

• Imatinib mesylate treatment in two patients with idiopathic hypereosinophilic syndrome.

  Payne SM, Kovacs MJ. Payne SM, et al. Ann Pharmacother. 2004 Jul-Aug;38(7-8):1215-8. doi: 10.1345/aph.1D505. Epub 2004 Jun 8. Ann Pharmacother. 2004. PMID: 15187212

• Treatment of idiopathic hypereosinophilic syndrome with imatinib mesylate.

  Garg A, Duggal L, Aggarwal S, Jain N. Garg A, et al. J Assoc Physicians India. 2006 Nov;54:883-6. J Assoc Physicians India. 2006. PMID: 17249259

• Imatinib mesylate for the treatment of hypereosinophilic syndromes.

  Antoniu SA. Antoniu SA. Curr Opin Investig Drugs. 2006 Nov;7(11):980-4. Curr Opin Investig Drugs. 2006. PMID: 17117585 Review.

• Bullous pemphigoid associated with hypereosinophilic syndrome: simultaneous response to imatinib.

  Hofmann SC, Technau K, Müller AM, Lübbert M, Bruckner-Tuderman L. Hofmann SC, et al. J Am Acad Dermatol. 2007 May;56(5 Suppl):S68-72. doi: 10.1016/j.jaad.2006.02.059. Epub 2006 Aug 28. J Am Acad Dermatol. 2007. PMID: 17097375 Review.

Cited by

• Imatinib-Associated Tumor Lysis Syndrome in a Patient With Myeloid Neoplasm With Eosinophilia and PDGFRA Rearrangement: A Case Report and Review of the Literature.

  Socola F, Hawes V, Lobo RH, Sasapu A. Socola F, et al. J Glob Oncol. 2018 Sep;4:1-4. doi: 10.1200/JGO.2016.007716. Epub 2017 Feb 8. J Glob Oncol. 2018. PMID: 30241197 Free PMC article. Review. No abstract available.

• Concurrent eosinophilia and IgG4-related disease in a child: A case report and review of the literature.

  Chen C, Chen K, Huang X, Wang K, Qian S. Chen C, et al. Exp Ther Med. 2018 Mar;15(3):2739-2748. doi: 10.3892/etm.2018.5743. Epub 2018 Jan 12. Exp Ther Med. 2018. PMID: 29456677 Free PMC article.

• Paratrabecular myelofibrosis and occult mastocytosis are strong morphological clues to suspect FIP1L1-PDGFRA translocation in hypereosinophilia.

  Sreedharanunni S, Sachdeva MUS, Sharma S, Rana S, Sandal R, Kumar N, Sharma P, Naseem S, Ahluwalia J, Das R, Malhotra P, Varma N. Sreedharanunni S, et al. Indian J Hematol Blood Transfus. 2020 Apr;36(2):384-389. doi: 10.1007/s12288-019-01236-0. Epub 2019 Dec 4. Indian J Hematol Blood Transfus. 2020. PMID: 32425395 Free PMC article.

• Molecular Profiling of Exceptional Responders to Cancer Therapy.

  Bilusic M, Girardi D, Zhou Y, Jung K, Pei J, Slifker M, Chen Q, Meerzaman D, Alpaugh K, Young D, Flieder D, Gray P, Plimack E. Bilusic M, et al. Oncologist. 2021 Mar;26(3):186-195. doi: 10.1002/onco.13600. Epub 2020 Nov 28. Oncologist. 2021. PMID: 33210795 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Other Literature Sources

  • The Lens - Patent Citations Database